Evidence map›Paper›PMID 42666820›Full record

ArticleCureus2026

Metastatic Carotid Body Paraganglioma Following Three Decades of Indolent Growth: A Case Report.

Erik L Parkhurst, Amar Hamad

Abstract readCase Reports
In one paragraph

Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Erik L ParkhurstInternational Program, Universidad Autónoma de Guadalajara (UAG) School of Medicine, Zapopan, MEX.
Amar HamadHematology and Medical Oncology, Affiliated Oncologists, Chicago Ridge, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Paragangliomas (PGLs) are rare neuroendocrine tumors arising from extra-adrenal chromaffin cells, with head and neck paragangliomas (HNPGLs) accounting for only a small proportion of all cases. Although most HNPGLs are benign, slow-growing, and nonfunctional, a minority develop metastatic disease, for which reliable histopathologic predictors remain lacking. We report the case of a 63-year-old man who presented with a progressively enlarging left-sided neck mass that had been present for more than 30 years before evaluation. Imaging demonstrated a carotid body paraganglioma with cervical lymph node involvement and distant suspected metastases to the thoracic and lumbar spine, lung, salivary gland, shoulder soft tissue, and small bowel. Histopathology confirmed paraganglioma with classic Zellballen architecture and positive staining for synaptophysin, chromogranin-A, CD56, GATA3, and S100-positive sustentacular cells. Given the patient's minimal symptoms despite extensive metastatic disease, a multidisciplinary team initially pursued active surveillance with serial multimodal imaging. Radiographic progression over time prompted initiation of systemic therapy with cabozantinib, which resulted in decreased metabolic activity of the primary tumor and no fluorodeoxyglucose-avid evidence of metastatic disease on follow-up imaging. This case highlights the unpredictable biological behavior of carotid body paragangliomas, demonstrating that longstanding, minimally symptomatic tumors may ultimately progress to widespread metastatic disease. It further emphasizes the importance of prolonged surveillance, multimodal imaging, multidisciplinary management, and individualized treatment strategies for patients with metastatic HNPGLs in the absence of reliable predictors of malignant potential.

Indexed as

carotid body paragangliomahead and neck paragangliomametastatic paragangliomamultiorgan metastasesneuroendocrine tumor

Identifiers

PMID42666820
PMCPMC13524210

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.